Total Payments
$2.8M
2024 Payments
$476,573
Companies
30
Transactions
2,014
Medicare Patients
117
Medicare Billing
$15,444
Payment Breakdown by Category
Consulting$1.1M (39.6%)
Other$1.0M (37.3%)
Travel$590,804 (21.0%)
Food & Beverage$34,260 (1.2%)
Research$26,151 (0.9%)
Education$246.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.1M | 294 | 39.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 314 | 37.3% |
| Travel and Lodging | $590,804 | 817 | 21.0% |
| Food and Beverage | $34,260 | 522 | 1.2% |
| Unspecified | $26,151 | 60 | 0.9% |
| Grant | $495.00 | 1 | 0.0% |
| Education | $246.00 | 6 | 0.0% |
Payments by Type
General
$2.8M
1,954 transactions
Research
$26,151
60 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $649,493 | 469 | $0 (2024) |
| GENZYME CORPORATION | $580,628 | 337 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $513,160 | 435 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $299,435 | 296 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $288,691 | 106 | $0 (2024) |
| AstraZeneca UK Limited | $100,199 | 85 | $0 (2024) |
| AstraZeneca AB | $84,794 | 44 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $63,116 | 24 | $0 (2019) |
| Amgen Inc. | $39,287 | 29 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $37,089 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $476,573 | 291 | GlaxoSmithKline, LLC. ($154,373) |
| 2023 | $492,041 | 412 | GlaxoSmithKline, LLC. ($176,100) |
| 2022 | $452,306 | 301 | AstraZeneca Pharmaceuticals LP ($107,754) |
| 2021 | $245,678 | 159 | AstraZeneca Pharmaceuticals LP ($76,873) |
| 2020 | $229,653 | 163 | GlaxoSmithKline, LLC. ($66,985) |
| 2019 | $371,500 | 243 | SANOFI-AVENTIS U.S. LLC ($109,809) |
| 2018 | $276,153 | 212 | GENZYME CORPORATION ($81,927) |
| 2017 | $269,304 | 233 | AstraZeneca Pharmaceuticals LP ($65,445) |
All Payment Transactions
2,014 individual payment records from CMS Open Payments — Page 1 of 81
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| 12/20/2024 | GlaxoSmithKline, LLC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | — | Food and Beverage | In-kind items and services | $120.83 | General |
| 12/19/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $550.20 | General |
| 12/19/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $395.46 | General |
| 12/19/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $187.50 | General |
| 12/19/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $183.54 | General |
| 12/16/2024 | GlaxoSmithKline, LLC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,367.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $789.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,200.00 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $477.07 | General |
| 12/05/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $62.16 | General |
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| Category: Respiratory | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Respiratory | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $128.70 | General |
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $27.88 | General |
| 11/26/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,578.00 | General |
| 11/23/2024 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $497.89 | General |
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $420.80 | General |
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,762.00 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASTHMA EXACERBATION REDUCTION IN ADULTS WITH AIRWAY BRONCHODILATOR REVERSIBILITY AFTER OMALIZUMAB TREATMENT | F. Hoffmann-La Roche AG | $8,611 | 1 |
| Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study | GENZYME CORPORATION | $4,000 | 12 |
| Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of SAR231893/REGN668 Administered Subcutaneously Once Weekly for 12 Weeks in Patients With Persistent Moderate to Severe Eosinophilic Asthma Who Are Partially Controlled/Uncontrolled by Inhaled Corticosteroid Plus Long-acting beta2 Agonist Therapy | GENZYME CORPORATION | $2,500 | 6 |
| A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma | SANOFI US SERVICES INC. | $2,496 | 6 |
| A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MUL | GlaxoSmithKline, LLC. | $1,717 | 8 |
| A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | GENZYME CORPORATION | $1,250 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma | GENZYME CORPORATION | $1,250 | 1 |
| Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants | SANOFI-AVENTIS U.S. LLC | $863.08 | 2 |
| Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE) | SANOFI-AVENTIS U.S. LLC | $782.73 | 3 |
| Open label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma who particpated in previous dupilumab asthma clinical study | SANOFI-AVENTIS U.S. LLC | $671.95 | 2 |
| A randomized, double-blind, placebo-controlled, parallel-group, 12-week Proof-of-Concept study to assess the efficacy, safety, and tolerability of SAR440340, and the coadministration of SAR440340 and | SANOFI-AVENTIS U.S. LLC | $618.46 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 and Dupilumab in Patients With Moderate-to-severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting B2 Adrenergic Agonist (LABA) Therapy | GENZYME CORPORATION | $500.00 | 2 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 | SANOFI US SERVICES INC. | $347.45 | 10 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $299.41 | 4 |
| Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Patients | SANOFI-AVENTIS U.S. LLC | $244.62 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 19 | 25 | $5,167 | $2,694 |
| 2022 | 2 | 38 | 57 | $10,585 | $5,605 |
| 2021 | 2 | 31 | 41 | $7,470 | $4,106 |
| 2020 | 2 | 29 | 43 | $7,055 | $3,040 |
Total Patients
117
Total Services
166
Medicare Billing
$15,444
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 19 | 25 | $5,167 | $2,694 | 52.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 27 | 37 | $7,585 | $4,165 | 54.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 20 | $3,000 | $1,440 | 48.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 20 | 24 | $4,920 | $2,790 | 56.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 11 | 17 | $2,550 | $1,316 | 51.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 18 | 32 | $4,800 | $2,021 | 42.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 11 | 11 | $2,255 | $1,018 | 45.2% |
About Dr. Michael Wechsler, MD
Dr. Michael Wechsler, MD is a Critical Care Medicine healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528017993.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Wechsler, MD has received a total of $2.8M in payments from pharmaceutical and medical device companies, with $476,573 received in 2024. These payments were reported across 2,014 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($1.1M).
As a Medicare-enrolled provider, Wechsler has provided services to 117 Medicare beneficiaries, totaling 166 services with total Medicare billing of $15,444. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Denver, CO
- Active Since 05/10/2006
- Last Updated 11/12/2020
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1528017993
Products in Payments
- DUPIXENT (Biological) $414,127
- DUPIXENT (Drug) $313,684
- NUCALA (Biological) $239,675
- TEZSPIRE (Biological) $164,055
- FASENRA (Biological) $133,693
- DUPIXENT DUPILUMAB INJECTION (Biological) $74,028
- FASENRA (Drug) $60,678
- CINQAIR (Biological) $50,258
- NO PRODUCT DISCUSSED (Drug) $42,080
- AIRSUPRA (Drug) $31,878
- Xolair (Biological) $30,633
- SPIRIVA (Drug) $14,833
- STIOLTO RESPIMAT (Drug) $9,467
- XOLAIR (Biological) $8,878
- RESLIZUMAB (Drug) $7,642
- JOENJA (Drug) $6,998
- ALAIR (Device) $5,503
- CINQAIR (Drug) $5,216
- IGE025A (Biological) $3,903
- UTIBRON (Drug) $1,000
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Denver
Dr. Rebecca Keith, M.d, M.D
Critical Care Medicine — Payments: $264,380
Critical Care Medicine $264,380
Marjorie George, Md, MD
Critical Care Medicine — Payments: $227,937
Critical Care Medicine $227,937
Charles Daley, Md, MD
Critical Care Medicine — Payments: $150,259
Critical Care Medicine $150,259
Zulma Yunt, Md, MD
Critical Care Medicine — Payments: $93,837
Critical Care Medicine $93,837
Dr. Timmy Lahm, Md, MD
Critical Care Medicine — Payments: $54,623
Critical Care Medicine $54,623
Kristen Glisinski, M.d, M.D
Critical Care Medicine — Payments: $34,118
Critical Care Medicine $34,118